Risk-based postal import clearance standardises electronic assessment, document requests, duty realisation and delivery controls at Foreign Post Offic...
Customs Cargo Service Provider appointment extends custodianship to additional terminal land, subject to cargo-control, security and licence condition...
Post-search scrutiny assessment remains available where original assessment limitation is unexpired, permitting timely completion under regular assess...
The CESTAT held that insulin products manufactured using recombinant DNA technology would qualify as 'mono-component insulin' and are entitled to exemption under Notification No. 12/2012 Customs dated March 17, 2012, as they are lifesaving drugs. The classification of the imported insulin products is based on their content rather than source. The Tribunal accepted that 'mono-component' refers to the purity of insulin rather than its source, and there was no evidence that the disputed products had impurity levels higher than 1 PPM. The CESTAT upheld the classification of the imported insulin products under chapter heading 3004 31 10, making them eligible for the exemption as lifesaving drugs.
The CESTAT held that insulin products manufactured using recombinant DNA technology would qualify as 'mono-component insulin' and are entitled to exemption under Notification No. 12/2012 Customs dated March 17, 2012, as they are lifesaving drugs. The classification of the imported insulin products is based on their content rather than source. The Tribunal accepted that 'mono-component' refers to the purity of insulin rather than its source, and there was no evidence that the disputed products had impurity levels higher than 1 PPM. The CESTAT upheld the classification of the imported insulin products under chapter heading 3004 31 10, making them eligible for the exemption as lifesaving drugs.
Note: It is a system-generated summary and is for quick reference only.
TaxTMI 
Join Channel
TaxTMI 
